Create your own personalized MyJanssenCarePath account to:

  • Learn about specific insurance coverage options
  • Determine your eligibility to enroll in the Janssen CarePath Savings Program
  • Sign up for personal treatment reminders
Menu

Getting Started

Getting Started

Janssen CarePath provides the additional support you may need to help you get started with STELARA® treatment, once you and your doctor have decided that STELARA® is right for you. A personally assigned Janssen CarePath Care Coordinator will work closely with you and your doctor to provide the support you need.

Your Janssen CarePath Care Coordinator can:

  • Review your health plan benefits to help answer questions you may have about insurance coverage for STELARA®
  • Identify options that may help make STELARA® more affordable, if needed
  • Work with your specialty pharmacy to process and deliver your STELARA® medication to your home or your doctor’s office
  • Provide treatment education support. We also invite you to learn more at StelaraInfo.com

If you have any questions, please call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support is available.

Support

Get started with a Janssen CarePath account

Sign Up or Log In to your personal Janssen CarePath account so you can learn about your insurance coverage for STELARA®; if eligible, enroll in the Janssen CarePath Savings Program and manage program benefits; and sign up for treatment support that may help you start and stay on track with your Janssen medication.

Treatment Support

Download the Step-By-Step Guide to Getting Started with STELARA® for the approved indication of active psoriatic arthritis and the approved indication of moderate to severe plaque psoriasis

Download the 3 Steps to STELARA® for the approved indication of moderately to severely active Crohn’s disease

Learn more about your STELARA® treatment at StelaraInfo.com

If Your Health Plan Does Not Approve STELARA® Treatment

Sometimes you may not be able to obtain the medication that your doctor has ordered for you. For example, your health plan might not cover the medication because it is not on the plan’s drug list (formulary) or the cost is higher than you think you should have to pay. In these situations, you and your doctor have the right to ask the health plan to explain its decision and to consider making the medication available to you as an exception to its policies.

Janssen Link logo

Janssen Link enables eligible patients to receive STELARA® at no cost until you receive coverage or until the end of the current program year if the following program requirements are met.

Janssen Link Program Requirements

Janssen CarePath Patients
  • You have been prescribed subcutaneous STELARA® for an on-label, FDA-approved indication
  • You have commercial insurance that has delayed (>5 business days) or denied your treatment
  • You do not use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration
  • You cannot submit the value of the free product as a claim for payment to any third-party payer
  • You are not eligible if the prior authorization is denied due to missing information on coverage determination form, use for a non-FDA-approved indication, or invalid clinical rationale
  • You must contact Janssen CarePath if you switch from commercial health insurance coverage to a government-funded healthcare program at any point during the program year
Janssen CarePath HCP
  • Your prescriber must complete and submit an electronic enrollment in the Provider Portal or fax the Benefits Investigation and Prescription Information Form to Janssen CarePath to enroll patient in Janssen Link
    • Janssen CarePath cannot accept any information without an executed Business Associate Agreement or Patient Authorization on file. The patient authorization can be found on the Benefits Investigation and Prescription Information Form. Or you can create an account on MyJanssenCarePath.com and electronically sign a patient authorization there.
  • Your prescriber agrees to not purchase the Janssen medication on your behalf, and not bill commercial payers for any part of the prescribed subcutaneous treatment
  • Your prescriber completes and submits a form of coverage determination (ie, prior authorization or prior authorization with exception) to the commercial insurance
  • If coverage is denied, your prescriber challenges the coverage denial with an exception, Letter of Medical Necessity, or appeal

How Janssen Link Works

  • Program covers the cost of therapy only - not associated administration cost
  • No portion of the value of the free product will count towards the patient's applicable out-of-pocket cost-sharing obligations
  • Program year runs March 1 - February 28
  • Janssen CarePath reserves the right to cancel or modify Janssen Link at any time

Injection Support

A Nurse is Just a Phone Call Away

Even after you’ve been trained by a healthcare professional to give yourself an injection, you may still have questions. Janssen Nurse Support* can help answer questions about giving yourself an injection at home, preparing your injection site prior to self-injecting, and properly disposing of your used syringe.

Connect with Janssen Nurse Support at 877-CarePath (877-227-3728), available Monday - Friday, 9:00 AM to 8:00 PM ET. At all other times, a nurse will typically return your call in 15 minutes.

*Janssen Nurse Support is limited to education about your Janssen medication, its administration, and/or the condition it treats. It is not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

Step-by-step injection demonstration videos

You can watch these step-by-step injection dosing demonstration videos to be reminded how to take your STELARA® medication.

Click here for STELARA® injection demonstration video for the approved indication of active psoriatic arthritis or moderate to severe plaque psoriasis

Click here for STELARA® injection training overview video for the approved indications of moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis

Infusion Support

Infusion Site Locator
If your doctor’s office does not have an infusion center, use the search capabilities of 2infuse.com to help you locate an infusion site convenient to your home or doctor’s office. Searchable by city or ZIP Code, this helpful site provides detailed search results organized by driving distance. This website also includes valuable information about the infusion sites such as business hours, insurance plans accepted, and medications infused.

This website offers the user the opportunity to locate and contact an infusion site of care. Inclusion of centers in this database is based on opt-in approval by authorized personnel for those sites listed. This database is compiled for informational purposes only. No fees have been or will be received in exchange for participation in this database. In no event shall Janssen Biotech, Inc., or its employees or agents be liable for any damages resulting from or related to this service. All providers and other users of this information agree that use of this service is at their own risk.

Inclusion of centers in this database does not represent an endorsement, referral or recommendation from Janssen Biotech, Inc. Moreover, the infusion sites of care participating in this search feature do not necessarily endorse the use of any Janssen Biotech, Inc., products.

Janssen Biotech, Inc., makes no representations as to whether any of the infusion sites of care participating in this search feature are covered by particular healthcare plans or insurers, if at all. Importantly, insurance verification is ultimately the responsibility of the provider. Users of this website are solely responsible for communications and interactions with any of the listed facilities or physician offices, and any information users send them is not governed by our Legal Notice and Privacy Policy. Users are responsible for compliance with state and federal laws regulating physician referrals, such as anti-kickback laws, the Stark law, or state professional practice restrictions.

Health Plan Open Enrollment Information

Even if you keep the same health plan year to year, benefits can change. The information in the Open Enrollment Brochure can help you review your coverage and make changes if needed to stay on treatment in your new benefit period, usually beginning January 1.

Get Open Enrollment Brochure

If you’re enrolled in Medicare and using Medicare insurance to pay for your medications, our Medicare Resource Guide provides important information to consider as you are selecting your insurance coverage.

Get Medicare Resource Guide

If you have any questions, please call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support is available.

What is STELARA®?

STELARA® is a prescription medicine used to treat:

  • adults and children 12 years and older with moderate or severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
  • adults 18 years and older with active psoriatic arthritis. STELARA® can be used alone or with the medicine methotrexate.
  • adults 18 years and older with moderately to severely active Crohn’s disease.
  • adults 18 years and older with moderately to severely active ulcerative colitis.
Important Safety Information For STELARA®

STELARA® is a prescription medicine that affects your immune system. STELARA® can increase your chance of having serious side effects including:

Serious Infections

STELARA® may lower your ability to fight infections and may increase your risk of infections. While taking STELARA®, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

  • Your doctor should check you for TB before starting STELARA® and watch you closely for signs and symptoms of TB during treatment with STELARA®.
  • If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA®.

You should not start taking STELARA® if you have any kind of infection unless your doctor says it is okay.

Before starting STELARA®, tell your doctor if you:

  • think you have an infection or have symptoms of an infection such as:
    • fever, sweats, or chills
    • muscle aches
    • cough
    • shortness of breath
    • blood in phlegm
    • weight loss
    • warm, red, or painful skin or sores on your body
    • diarrhea or stomach pain
    • burning when you urinate or urinate more often than normal
    • feel very tired
  • are being treated for an infection or have any open cuts.
  • get a lot of infections or have infections that keep coming back.
  • have TB, or have been in close contact with someone with TB.

After starting STELARA®, call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. STELARA® can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL‐12) and interleukin 23 (IL‐23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® may also be more likely to get these infections.

Cancers

STELARA® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA®. Tell your doctor if you have any new skin growths.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

RPLS is a rare condition that affects the brain and can cause death. The cause of RPLS is not known. If RPLS is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious Allergic Reactions

Serious allergic reactions can occur. Stop using STELARA® and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Lung Inflammation

Cases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn’t go away during treatment with STELARA®.

Before receiving STELARA®, tell your doctor about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed above for serious infections, cancers, or RPLS.
  • ever had an allergic reaction to STELARA® or any of its ingredients. Ask your doctor if you are not sure.
  • are allergic to latex. The needle cover on the prefilled syringe contains latex.
  • have recently received or are scheduled to receive an immunization (vaccine). People who take STELARA® should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receiving STELARA® or one year after you stop receiving STELARA®.
  • have any new or changing lesions within psoriasis areas or on normal skin.
  • are receiving or have received allergy shots, especially for serious allergic reactions.
  • receive or have received phototherapy for your psoriasis.
  • are pregnant or plan to become pregnant. It is not known if STELARA® can harm your unborn baby. You and your doctor should decide if you will receive STELARA®.
  • are breastfeeding or plan to breastfeed. It is thought that STELARA® passes into your breast milk.
  • talk to your doctor about the best way to feed your baby if you receive STELARA®.

Tell your doctor about all the medicines you take, including prescription and over‐the‐counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed STELARA®:

  • Use STELARA® exactly as your doctor tells you to.
  • STELARA® is intended for use under the guidance and supervision of your doctor. In children 12 years and older, it is recommended that STELARA® be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of STELARA® at home, you should receive training on the right way to prepare and inject STELARA®. Your doctor will determine the right dose of STELARA® for you, the amount for each injection, and how often you should receive it. Do not try to inject STELARA® yourself until you or your caregiver have been shown how to inject STELARA® by your doctor or nurse.

Common side effects of STELARA® include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with STELARA®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full Prescribing Information and Medication Guide for STELARA® and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.

cp-124932v1